Miyastenia Graviste Anksiyete ve Depresif Belirtilerin, Hastalık Şiddeti ve Tedavi Biçimiyle İlişkisi: Kesitsel Bir Çalışma

Aysal, Fikret; Karamustafalıoğlu, Oğuz; Özçelik, Başak; Yılmaz, Meltem; Karamustafalıoğlu, Nesrin; Yumrukçal, Hüseyin; Tankaya, Onur

doi:10.4274/npa.y5611

Cited by 22 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The study confirmed the hypothesis of the severity of depression on the degree of clinical manifestations of myasthenia gravis. These findings reflect the results in other studies [9,12].…”

Section: The Average Level Of Depression In Patients With Myasthenia supporting

confidence: 92%

“…To date, the literature provides guidance on the effect of anticholinesterase, prednisolone and azathioprine on the development of depression [9,10,12,13]. According to our study, this effect has not been confirmed.…”

Section: The Average Level Of Depression In Patients With Myasthenia mentioning

confidence: 63%

“…However, our study did not examine the relationship between doses of these drugs and the development of depression. This requires further study, because, for example, a dose-dependent effect of corticosteroid intake on the development of psycho-emotional changes has been established [10,12].…”

Section: The Average Level Of Depression In Patients With Myasthenia mentioning

confidence: 99%

See 2 more Smart Citations

Features of depression development in myasthenia gravis.

Kalbus¹,

Makarov²,

Shastun³

et al. 2020

Medicni Perspektivi (Medical Perspectives)

View full text Add to dashboard Cite

Features of depression development in myasthenia gravis. Kalbus O.I., Makarov S.O., Shastun N.P., Somilo O.V., Bukreyeva Yu.V. The relative risk of developing depression in myasthenia gravis is 2.14 times higher than in the general population. The features of depression in myasthenia patients remain poorly understood and need to be clarified. The purpose of this work was to study the features of the development of depression in patients with myasthenia gravis. From 2014 to 2017, 182 patients with myasthenia gravis were examined. 147 (80.8%) patients had a generalized form of the disease, 35 (19.2%) had an ocular form. The clinical examination included assessment of complaints, medical history, neurological examination, as well as MGFA (Myasthenia Gravis Foundation of America) disease class and subclass of the disease determination. The severity of myasthenia gravis has been quantified according to the QMG score (Quantitative Myasthenia Gravis Score). All the patients were examined for the titer of antibodies to acetylcholine receptors (AchR) and muscle-specific tyrosine kinase (MuSK) by enzyme-linked immunosorbent assay (ELISA). Patients were also tested for the presence of antibodies to titin and SOX1 by indirect immunofluorescence. To detect depression the Beck depression inventory (BDI) was used. The mean depression score in the total sample was 16.0 (10.0; 24.0), which corresponds to a moderate depression level. The mean depression score in patients with ocular form was 6.0 (3.0; 11.0) points (ie, depression is absent), whereas in patients with generalized myasthenia gravis-19.0 (12.0; 29.0) points (corresponds to moderate depression) (p <0.001). The distribution of patients with mild depression was also uneven: significantly bigger part of the patients was recorded with myasthenia gravis of class I (ocular form)-10 (28.6%), and with myasthenia gravis of class II-23 (44.2%). Among the patients with myasthenia gravis of class III, only 13 (20.3%) patients were reported with mild depression and 1 (3.2%) with class IV, p<0.001. The distribution of patients with moderate depression was the opposite of others: most patients had myasthenia gravis of class II-12 (18.8%), and there were no patients with myasthenia gravis of class I. A similar tendency is also observed in the case of severe depression: patients with myasthenia gravis of class II-23 (35.6%) dominated, to a lesser extent-patients with myasthenia gravis of class IV-6 (19.4%). Among patients with ocular myasthenia gravis, only 1 (2.9%) patient was found to have severe depression. Severe depression was mainly recorded in patients with myasthenia gravis of class IV-22 (71%) patients. The number of patients with severe depression has been decreased in the class of myasthenia gravis: 13 patients (20.3%) patients with ІІІ class, 1 (1.9%) with II class, no patients with class I. The degree of depression correlates with the clinical form of myasthenia gravis (ρ=-0.52; p<0.001), class (ρ=-0.30; p<0.001) and the subclass of the disease according to MGFA (ρ=-0.36; ...

show abstract

“…The study confirmed the hypothesis of the severity of depression on the degree of clinical manifestations of myasthenia gravis. These findings reflect the results in other studies [9,12].…”

Section: The Average Level Of Depression In Patients With Myasthenia supporting

confidence: 92%

Section: The Average Level Of Depression In Patients With Myasthenia mentioning

confidence: 63%

See 1 more Smart Citation

Features of depression development in myasthenia gravis.

Kalbus¹,

Makarov²,

Shastun³

et al. 2020

Medicni Perspektivi (Medical Perspectives)

View full text Add to dashboard Cite

show abstract

“…Враховуючи хронічний характер захворювання, у хворих на міастенію можуть розвиватися психоло-гічні та психічні порушення, в тому числі депресія та підвищена тривожність, які можуть впливати на якість життя хворих з одного боку, та бути предик-тором «псевдо-декомпенсації» хворих з іншого [6,7]. Якість життя хворих на міастенію на даний час в Україні вивчена недостатньо та потребує подальшого вивчення з метою оптимізації лікувальних підходів та підвищення соціальної активності.…”

Section: вступunclassified

“…Розвиток станів дезадаптації студентів протягом професійного нав-чання є головною психологічною, медичною та со-ціально-економічною проблемою, що несприятливо позначається на ефективності майбутньої професій-ної діяльності студентів медиків [7,8].…”

Section: вступunclassified

Assessment of quality of life in patients with myasthenia

Kalbus¹

2018

ScienceRise: Medical Science

View full text Add to dashboard Cite

Prevalence of depression and anxiety among myasthenia gravis (MG) patients: A systematic review and meta‐analysis

et al. 2022

View full text Add to dashboard Cite

Objective Myasthenia gravis (MG) people experience adverse psychiatric outcomes, which may impact on their life and disturb their daily activity. Depression and anxiety are identified as significant psychiatric problems that MG people face. However, there is no sufficient epidemiological information about depression and anxiety‐based publication. Due to this limitation, the aim of this study was to review the prevalence of depression and anxiety in MG patients. Methods Original and international databases were searched to find papers about the estimation of anxiety and depression. Random‐effects analysis was used for calculating the proportions of anxiety and depression. For estimating anxiety and depression based the severity, instruments, type of studies, and study regions, subgroup analysis was performed. Results 38 studies met inclusion criteria and entered study. The pooling of the prevalence of depression was found at 36%, (95% CI 28% to 45%). Also, prevalence of anxiety was found at 33%, (95% CI 25% to 42%). Prevalence of depression based on mild, moderate, and severe level was 27%, 14%, and 9%, respectively. Conclusions Anxiety and depression are a major concern among MG individuals. The estimation of both anxiety and depression are high even when compared to other autoimmune diseases. It seems depression and anxiety are important issues and more attention needs to be paid to these psychiatric disorders.

show abstract

Miyastenia Graviste Anksiyete ve Depresif Belirtilerin, Hastalık Şiddeti ve Tedavi Biçimiyle İlişkisi: Kesitsel Bir Çalışma

Abstract: The results of the present study may suggest that patients with relatively more severe MG or those taking a combination of immunosupressive and anticholinesterase medications need psychiatric/psychological evaluation.

Cited by 22 publications

References 21 publications

Features of depression development in myasthenia gravis.

Features of depression development in myasthenia gravis.

Assessment of quality of life in patients with myasthenia

Prevalence of depression and anxiety among myasthenia gravis (MG) patients: A systematic review and meta‐analysis

Contact Info

Product

Resources

About